Wingtech fait geler l’équivalent de 270 M€ d’actifs de Nexperia
东莞法院近日下达保全裁定，冻结了 Nexperia 旗下多家中国子公司的资产，涉及金额相当于约 2.7 亿欧元。这一措施发生在 Nexperia 与其中国母公司 Wingtech 的争议背景下，属于双方纠纷中的最新进展。
面对这一决定，Nexperia 方面刻意淡化影响，表示该裁定不会波及公司的日常运营、管理层运作，也不会影响其业务连续性。换言之，尽管法院采取了资产保全措施，Nexperia 强调其生产经营仍将按原计划推进。
目前公开信息显示，此次冻结针对的是 Nexperia 在中国的若干子公司，但报道未披露更具体的资产范围或争议细节。整体来看，这一裁定反映出 Wingtech 与 Nexperia 之间的法律纠纷仍在升级，而 Nexperia 则试图向外界传递“运营不受影响”的稳定信号。
The Dongguan court has ordered a precautionary seizure of several Chinese subsidiaries of Nexperia, escalating the dispute between the Dutch chipmaker and its Chinese parent company, Wingtech. The measure affects assets worth the equivalent of about €270 million.
Nexperia is downplaying the impact of the ruling, saying it does not affect day-to-day operations, management, or the continuity of its business. The company insists that its activities continue normally despite the legal action.
The case underscores the ongoing tensions between Nexperia and Wingtech, with the Dongguan decision marking a significant step in the broader corporate conflict.
Le tribunal de Dongguan vient d’ordonner la saisie conservatoire de plusieurs filiales chinoises de Nexperia, dans le cadre du litige qui l’oppose à sa maison mère chinoise Wingtech. Le Néerlandais minimise l’impact de cette décision, précisant qu’elle n’affecte ni les opérations courantes, ni la gestion, ni la continuité de ses activités. Petit rappel des faits […]
Cet article Wingtech fait geler l’équivalent de 270 M€ d’actifs de Nexperia a été publié par VIPress.net.
A Dongguan court ordered a conservative asset seizure of multiple Nexperia China subsidiaries (~€270M equivalent) in a dispute with parent Wingtech, raising counterparty and liquidity risk despite claims of no operational disruption.
Nexperia — Dutch semiconductor manufacturer; headquartered in the Netherlands.
Wingtech — Chinese parent company in a legal dispute with Nexperia; based in China.
Dongguan court (China) — Local judiciary ordering the seizure; based in Dongguan, China.
[Monitor] — watch for escalation, settlement outcomes, and any knock-on effects on Nexperia’s China operations and financing.